APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumonia Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pneumonia Treatment Drugs Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchPneumonia Treatment Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumonia Treatment Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Pneumonia Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumonia Treatment Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumonia Treatment Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pneumonia Treatment Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pneumonia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumonia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumonia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pneumonia Treatment Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pneumonia Treatment Drugs market include Teva Pharmaceutical, Sun Pharmaceutical, Novartis, Mylan, Pfizer, GlaxoSmithKline, AstraZeneca, Theravance Biopharma and Shinogi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumonia Treatment Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumonia Treatment Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumonia Treatment Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumonia Treatment Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumonia Treatment Drugs Segment by Company

Teva Pharmaceutical

Sun Pharmaceutical

Novartis

Mylan

Pfizer

GlaxoSmithKline

AstraZeneca

Theravance Biopharma

Shinogi

MSD

Medicines

Combioxin

Arsanis

Pneumonia Treatment Drugs Segment by Type

Vaccines

Vancomycin

Cephalosporin

Tetracyclines

Penicillin

Other Antibiotics

Immunotherapy Drug

Interferon

Fluoroquinolones

Macrolides

Pneumonia Treatment Drugs Segment by Application

Hospital

Clinic

Drugstore

Pneumonia Treatment Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pneumonia Treatment Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pneumonia Treatment Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumonia Treatment Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumonia Treatment Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumonia Treatment Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumonia Treatment Drugs industry.

Chapter 3: Detailed analysis of Pneumonia Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pneumonia Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pneumonia Treatment Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumonia Treatment Drugs Industry Trends Table 2. Pneumonia Treatment Drugs Industry Drivers Table 3. Pneumonia Treatment Drugs Industry Opportunities and Challenges Table 4. Pneumonia Treatment Drugs Industry Restraints Table 5. Global Pneumonia Treatment Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumonia Treatment Drugs Revenue Share by Company (2021-2026) Table 7. Global Pneumonia Treatment Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Pneumonia Treatment Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Pneumonia Treatment Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Pneumonia Treatment Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pneumonia Treatment Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Pneumonia Treatment Drugs Company, Product Type & Application Table 13. Global Pneumonia Treatment Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumonia Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vaccines Table 18. Significant Companies of Vancomycin Table 19. Significant Companies of Cephalosporin Table 20. Significant Companies of Tetracyclines Table 21. Significant Companies of Penicillin Table 22. Significant Companies of Other Antibiotics Table 23. Significant Companies of Immunotherapy Drug Table 24. Significant Companies of Interferon Table 25. Significant Companies of Fluoroquinolones Table 26. Significant Companies of Macrolides Table 27. Global Pneumonia Treatment Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Pneumonia Treatment Drugs Sales Volume by Type (2021-2026) & (k units) Table 29. Global Pneumonia Treatment Drugs Sales Volume by Type (2027-2032) & (k units) Table 30. Global Pneumonia Treatment Drugs Sales Volume Share by Type (2021-2026) Table 31. Global Pneumonia Treatment Drugs Sales Volume Share by Type (2027-2032) Table 32. Global Pneumonia Treatment Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pneumonia Treatment Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 34. Global Pneumonia Treatment Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 35. Global Pneumonia Treatment Drugs Sales Value Share by Type (2021-2026) Table 36. Global Pneumonia Treatment Drugs Sales Value Share by Type (2027-2032) Table 37. Significant Companies of Hospital Table 38. Significant Companies of Clinic Table 39. Significant Companies of Drugstore Table 40. Global Pneumonia Treatment Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Pneumonia Treatment Drugs Sales Volume by Application (2021-2026) & (k units) Table 42. Global Pneumonia Treatment Drugs Sales Volume by Application (2027-2032) & (k units) Table 43. Global Pneumonia Treatment Drugs Sales Volume Share by Application (2021-2026) Table 44. Global Pneumonia Treatment Drugs Sales Volume Share by Application (2027-2032) Table 45. Global Pneumonia Treatment Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Pneumonia Treatment Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 47. Global Pneumonia Treatment Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 48. Global Pneumonia Treatment Drugs Sales Value Share by Application (2021-2026) Table 49. Global Pneumonia Treatment Drugs Sales Value Share by Application (2027-2032) Table 50. Global Pneumonia Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 51. Global Pneumonia Treatment Drugs Sales by Region (2021-2026) & (k units) Table 52. Global Pneumonia Treatment Drugs Sales Market Share by Region (2021-2026) Table 53. Global Pneumonia Treatment Drugs Sales by Region (2027-2032) & (k units) Table 54. Global Pneumonia Treatment Drugs Sales Market Share by Region (2027-2032) Table 55. Global Pneumonia Treatment Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Pneumonia Treatment Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 57. Global Pneumonia Treatment Drugs Sales Value Share by Region (2021-2026) Table 58. Global Pneumonia Treatment Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 59. Global Pneumonia Treatment Drugs Sales Value Share by Region (2027-2032) Table 60. Global Pneumonia Treatment Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 61. Global Pneumonia Treatment Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 62. Global Pneumonia Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 63. Global Pneumonia Treatment Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Pneumonia Treatment Drugs Sales by Country (2021-2026) & (k units) Table 65. Global Pneumonia Treatment Drugs Sales Market Share by Country (2021-2026) Table 66. Global Pneumonia Treatment Drugs Sales by Country (2027-2032) & (k units) Table 67. Global Pneumonia Treatment Drugs Sales Market Share by Country (2027-2032) Table 68. Global Pneumonia Treatment Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 69. Global Pneumonia Treatment Drugs Sales Value Market Share by Country (2021-2026) Table 70. Global Pneumonia Treatment Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 71. Global Pneumonia Treatment Drugs Sales Value Market Share by Country (2027-2032) Table 72. Teva Pharmaceutical Company Information Table 73. Teva Pharmaceutical Business Overview Table 74. Teva Pharmaceutical Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Pneumonia Treatment Drugs Product Portfolio Table 76. Teva Pharmaceutical Recent Development Table 77. Sun Pharmaceutical Company Information Table 78. Sun Pharmaceutical Business Overview Table 79. Sun Pharmaceutical Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Sun Pharmaceutical Pneumonia Treatment Drugs Product Portfolio Table 81. Sun Pharmaceutical Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Novartis Pneumonia Treatment Drugs Product Portfolio Table 86. Novartis Recent Development Table 87. Mylan Company Information Table 88. Mylan Business Overview Table 89. Mylan Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Mylan Pneumonia Treatment Drugs Product Portfolio Table 91. Mylan Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Pfizer Pneumonia Treatment Drugs Product Portfolio Table 96. Pfizer Recent Development Table 97. GlaxoSmithKline Company Information Table 98. GlaxoSmithKline Business Overview Table 99. GlaxoSmithKline Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline Pneumonia Treatment Drugs Product Portfolio Table 101. GlaxoSmithKline Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. AstraZeneca Pneumonia Treatment Drugs Product Portfolio Table 106. AstraZeneca Recent Development Table 107. Theravance Biopharma Company Information Table 108. Theravance Biopharma Business Overview Table 109. Theravance Biopharma Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Theravance Biopharma Pneumonia Treatment Drugs Product Portfolio Table 111. Theravance Biopharma Recent Development Table 112. Shinogi Company Information Table 113. Shinogi Business Overview Table 114. Shinogi Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Shinogi Pneumonia Treatment Drugs Product Portfolio Table 116. Shinogi Recent Development Table 117. MSD Company Information Table 118. MSD Business Overview Table 119. MSD Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. MSD Pneumonia Treatment Drugs Product Portfolio Table 121. MSD Recent Development Table 122. Medicines Company Information Table 123. Medicines Business Overview Table 124. Medicines Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Medicines Pneumonia Treatment Drugs Product Portfolio Table 126. Medicines Recent Development Table 127. Combioxin Company Information Table 128. Combioxin Business Overview Table 129. Combioxin Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Combioxin Pneumonia Treatment Drugs Product Portfolio Table 131. Combioxin Recent Development Table 132. Arsanis Company Information Table 133. Arsanis Business Overview Table 134. Arsanis Pneumonia Treatment Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Arsanis Pneumonia Treatment Drugs Product Portfolio Table 136. Arsanis Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Pneumonia Treatment Drugs Distributors List Table 140. Pneumonia Treatment Drugs Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Pneumonia Treatment Drugs Product Image Figure 2. Global Pneumonia Treatment Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumonia Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pneumonia Treatment Drugs Sales (2021-2032) & (k units) Figure 5. Global Pneumonia Treatment Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Pneumonia Treatment Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vaccines Image Figure 10. Vancomycin Image Figure 11. Cephalosporin Image Figure 12. Tetracyclines Image Figure 13. Penicillin Image Figure 14. Other Antibiotics Image Figure 15. Immunotherapy Drug Image Figure 16. Interferon Image Figure 17. Fluoroquinolones Image Figure 18. Macrolides Image Figure 19. Global Pneumonia Treatment Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Pneumonia Treatment Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Pneumonia Treatment Drugs Sales Volume Share by Type (2021-2032) Figure 22. Global Pneumonia Treatment Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pneumonia Treatment Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Pneumonia Treatment Drugs Sales Value Share by Type (2021-2032) Figure 25. Hospital Image Figure 26. Clinic Image Figure 27. Drugstore Image Figure 28. Global Pneumonia Treatment Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 29. Global Pneumonia Treatment Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 30. Global Pneumonia Treatment Drugs Sales Volume Share by Application (2021-2032) Figure 31. Global Pneumonia Treatment Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Pneumonia Treatment Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 33. Global Pneumonia Treatment Drugs Sales Value Share by Application (2021-2032) Figure 34. Global Pneumonia Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 35. Global Pneumonia Treatment Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 36. Global Pneumonia Treatment Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 37. Global Pneumonia Treatment Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 38. North America Pneumonia Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. North America Pneumonia Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Europe Pneumonia Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Europe Pneumonia Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Asia-Pacific Pneumonia Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Asia-Pacific Pneumonia Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. South America Pneumonia Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 45. South America Pneumonia Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 46. Middle East & Africa Pneumonia Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 47. Middle East & Africa Pneumonia Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 48. USA Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. USA Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. USA Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Canada Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Canada Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Canada Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Mexico Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Mexico Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Mexico Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Germany Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Germany Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Germany Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. France Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. France Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. France Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. U.K. Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. U.K. Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. U.K. Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Italy Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Italy Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Italy Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Spain Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Spain Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Spain Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Russia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Russia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Russia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Netherlands Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Netherlands Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Netherlands Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Nordic Countries Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Nordic Countries Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Nordic Countries Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. China Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. China Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. China Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Japan Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Japan Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Japan Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. South Korea Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. South Korea Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. South Korea Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. India Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. India Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. India Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Australia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Australia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Australia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Southeast Asia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Southeast Asia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Southeast Asia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Brazil Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Brazil Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Brazil Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Argentina Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Argentina Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Argentina Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Chile Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Chile Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Chile Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Colombia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Colombia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Colombia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Peru Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Peru Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Peru Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Saudi Arabia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Saudi Arabia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Israel Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Israel Arabia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Israel Arabia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. UAE Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. UAE Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. UAE Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Turkey Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Turkey Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Turkey Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Iran Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Iran Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Iran Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Egypt Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 130. Egypt Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 131. Egypt Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 132. Pneumonia Treatment Drugs Value Chain Figure 133. Manufacturing Cost Structure Figure 134. Pneumonia Treatment Drugs Sales Mode & Process Figure 135. Direct Comparison with Distribution Share Figure 136. Distributors Profiles Figure 137. Years Considered Figure 138. Research Process Figure 139. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Vancomycin
  • Cephalosporin
  • Tetracyclines
  • Penicillin
  • Other Antibiotics
  • Immunotherapy Drug
  • Interferon
  • Fluoroquinolones
  • Macrolides
Applications
  • Hospital
  • Clinic
  • Drugstore
Companies covered
  • Teva Pharmaceutical
  • Sun Pharmaceutical
  • Novartis
  • Mylan
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Theravance Biopharma
  • Shinogi
  • MSD
  • Medicines
  • Combioxin
  • Arsanis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pneumonia Treatment Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Pneumonia Treatment Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Pneumonia Treatment Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pneumonia Treatment Drugs Market Dynamics
  1. 2.1 Pneumonia Treatment Drugs Industry Trends
  2. 2.2 Pneumonia Treatment Drugs Industry Drivers
  3. 2.3 Pneumonia Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 Pneumonia Treatment Drugs Industry Restraints
3 Pneumonia Treatment Drugs Market by Company
  1. 3.1 Global Pneumonia Treatment Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Pneumonia Treatment Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Pneumonia Treatment Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Pneumonia Treatment Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Pneumonia Treatment Drugs Company Ranking (2024-2026)
  6. 3.6 Global Pneumonia Treatment Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Pneumonia Treatment Drugs Company Product Type and Application
  8. 3.8 Global Pneumonia Treatment Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pneumonia Treatment Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pneumonia Treatment Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pneumonia Treatment Drugs Market by Type
  1. 4.1 Pneumonia Treatment Drugs Type Introduction
  2. 4.1.1 Vaccines
  3. 4.1.2 Vancomycin
  4. 4.1.3 Cephalosporin
  5. 4.1.4 Tetracyclines
  6. 4.1.5 Penicillin
  7. 4.1.6 Other Antibiotics
  8. 4.1.7 Immunotherapy Drug
  9. 4.1.8 Interferon
  10. 4.1.9 Fluoroquinolones
  11. 4.1.10 Macrolides
  12. 4.2 Global Pneumonia Treatment Drugs Sales Volume by Type
  13. 4.2.1 Global Pneumonia Treatment Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Pneumonia Treatment Drugs Sales Volume by Type (2021-2032)
  15. 4.2.3 Global Pneumonia Treatment Drugs Sales Volume Share by Type (2021-2032)
  16. 4.3 Global Pneumonia Treatment Drugs Sales Value by Type
  17. 4.3.1 Global Pneumonia Treatment Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Pneumonia Treatment Drugs Sales Value by Type (2021-2032)
  19. 4.3.3 Global Pneumonia Treatment Drugs Sales Value Share by Type (2021-2032)
5 Pneumonia Treatment Drugs Market by Application
  1. 5.1 Pneumonia Treatment Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Drugstore
  5. 5.2 Global Pneumonia Treatment Drugs Sales Volume by Application
  6. 5.2.1 Global Pneumonia Treatment Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumonia Treatment Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pneumonia Treatment Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pneumonia Treatment Drugs Sales Value by Application
  10. 5.3.1 Global Pneumonia Treatment Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pneumonia Treatment Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pneumonia Treatment Drugs Sales Value Share by Application (2021-2032)
6 Pneumonia Treatment Drugs Regional Sales and Value Analysis
  1. 6.1 Global Pneumonia Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumonia Treatment Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumonia Treatment Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Pneumonia Treatment Drugs Sales by Region (2027-2032)
  5. 6.3 Global Pneumonia Treatment Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pneumonia Treatment Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pneumonia Treatment Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pneumonia Treatment Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Pneumonia Treatment Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pneumonia Treatment Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Pneumonia Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pneumonia Treatment Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Pneumonia Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pneumonia Treatment Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pneumonia Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pneumonia Treatment Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Pneumonia Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pneumonia Treatment Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pneumonia Treatment Drugs Sales Value Share by Country, 2025 VS 2032
7 Pneumonia Treatment Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Pneumonia Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumonia Treatment Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pneumonia Treatment Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Pneumonia Treatment Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Pneumonia Treatment Drugs Sales by Country (2027-2032)
  6. 7.4 Global Pneumonia Treatment Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pneumonia Treatment Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pneumonia Treatment Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pneumonia Treatment Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pneumonia Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pneumonia Treatment Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Pneumonia Treatment Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sun Pharmaceutical
  8. 8.2.1 Sun Pharmaceutical Company Information
  9. 8.2.2 Sun Pharmaceutical Business Overview
  10. 8.2.3 Sun Pharmaceutical Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Pneumonia Treatment Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Pneumonia Treatment Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Pneumonia Treatment Drugs Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Pneumonia Treatment Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Pneumonia Treatment Drugs Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Pneumonia Treatment Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Theravance Biopharma
  44. 8.8.1 Theravance Biopharma Company Information
  45. 8.8.2 Theravance Biopharma Business Overview
  46. 8.8.3 Theravance Biopharma Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Theravance Biopharma Pneumonia Treatment Drugs Product Portfolio
  48. 8.8.5 Theravance Biopharma Recent Developments
  49. 8.9 Shinogi
  50. 8.9.1 Shinogi Company Information
  51. 8.9.2 Shinogi Business Overview
  52. 8.9.3 Shinogi Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Shinogi Pneumonia Treatment Drugs Product Portfolio
  54. 8.9.5 Shinogi Recent Developments
  55. 8.10 MSD
  56. 8.10.1 MSD Company Information
  57. 8.10.2 MSD Business Overview
  58. 8.10.3 MSD Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 MSD Pneumonia Treatment Drugs Product Portfolio
  60. 8.10.5 MSD Recent Developments
  61. 8.11 Medicines
  62. 8.11.1 Medicines Company Information
  63. 8.11.2 Medicines Business Overview
  64. 8.11.3 Medicines Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Medicines Pneumonia Treatment Drugs Product Portfolio
  66. 8.11.5 Medicines Recent Developments
  67. 8.12 Combioxin
  68. 8.12.1 Combioxin Company Information
  69. 8.12.2 Combioxin Business Overview
  70. 8.12.3 Combioxin Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Combioxin Pneumonia Treatment Drugs Product Portfolio
  72. 8.12.5 Combioxin Recent Developments
  73. 8.13 Arsanis
  74. 8.13.1 Arsanis Company Information
  75. 8.13.2 Arsanis Business Overview
  76. 8.13.3 Arsanis Pneumonia Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Arsanis Pneumonia Treatment Drugs Product Portfolio
  78. 8.13.5 Arsanis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumonia Treatment Drugs Value Chain Analysis
  2. 9.1.1 Pneumonia Treatment Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumonia Treatment Drugs Sales Mode & Process
  6. 9.2 Pneumonia Treatment Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumonia Treatment Drugs Distributors
  9. 9.2.3 Pneumonia Treatment Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst